How much does 2016 WHO classification of myeloproliferative neoplasms affect the clinic?

Expert Rev Hematol. 2019 Jul;12(7):473-476. doi: 10.1080/17474086.2019.1623019. Epub 2019 Jun 4.

Authors

Bruno Cassinat^{1

2}, Stephane Giraudier^{1

2

3}, Jean-Jacques Kiladjian^{2

3

4}

Affiliations

¹ a APHP, Hopital Saint-Louis, Service de Biologie Cellulaire , Paris , France.
² b Inserm UMRS-1131, IUH, Hopital Saint-Louis , Paris , France.
³ c Université Paris-Diderot , Paris , France.
⁴ d APHP, Hopital Saint-Louis, Centre d'Investigations Cliniques , Paris , France.

PMID: 31161817
DOI: 10.1080/17474086.2019.1623019

No abstract available

Publication types

Review

MeSH terms

Biomarkers
Combined Modality Therapy
Diagnosis, Differential
Disease Management
Disease Susceptibility
Humans
Myeloproliferative Disorders / diagnosis*
Myeloproliferative Disorders / etiology
Myeloproliferative Disorders / therapy*
Outcome Assessment, Health Care
Practice Guidelines as Topic* / standards
Treatment Outcome
World Health Organization*

Substances

Biomarkers